SurgMark’s biopsy marker will become a standard diagnostic process, to mark breast cancer lesions prior to neoadjuvant therapy and surgery. Our marker hits a growing market (CAGR 10%) with a volume of ~100 M $. FDA approval will be in 2021, sales in US starts in January 2022. Term sheet and LOI negotiations with strategic partners are ongoing. We are raising 950k EUR; closing is December 2019.